Mefenamic Acid + Tranexamic AcidThird Party Manufacturing in India

Mefenamic Acid + Tranexamic Acid works through two complementary mechanisms to manage pain and control excessive bleeding. Mefenamic acid is a nonsteroidal anti-inflammatory drug (NSAID) belonging to the fenamate class. It inhibits the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, blocking the conversion of arachidonic acid into prostaglandins. This reduces pain perception, inflammation, and fever. The analgesic effect is particularly useful for dysmenorrhea and other pelvic pain conditions where prostaglandin levels are elevated. Tranexamic acid acts as an antifibrinolytic agent by competitively blocking the binding of plasminogen to fibrin, preventing its activation to plasmin. Plasmin is the enzyme responsible for degrading fibrin clots, so by inhibiting its formation, tranexamic acid stabilizes existing blood clots and prevents excessive bleeding from small blood vessels. In the context of menorrhagia, where elevated endometrial fibrinolysis contributes to heavy menstrual bleeding, tranexamic acid significantly reduces blood loss without affecting the normal coagulation cascade. Together, the combination provides both symptomatic pain relief and objective reduction in blood loss, making it a highly effective dual-action therapy for conditions involving both pain and hemorrhage.

Therapeutic Uses

Mefenamic Acid + Tranexamic Acid is prescribed for:

• Menorrhagia (Heavy Menstrual Bleeding): Reducing excessive menstrual blood loss and alleviating associated dysmenorrhea in women with regular ovulatory cycles.
• Dysmenorrhea: Relieving painful menstrual cramps by reducing uterine prostaglandin levels and stabilizing endometrial hemostasis.
• Post-Surgical Bleeding: Managing mild to moderate bleeding following gynecological or dental procedures where both pain control and hemostasis are required.
• Epistaxis (Nosebleeds): Controlling recurrent or persistent nosebleeds where concomitant pain management is needed.

Why Manufacturers Choose Mefenamic Acid + Tranexamic Acid

This fixed-dose combination addresses a very specific and high-volume therapeutic need — the management of heavy menstrual bleeding, which affects approximately one in five women of reproductive age worldwide. The global prevalence of menorrhagia ensures a large and stable patient population, with repeat monthly prescriptions generating consistent demand. The dual mechanism combining a fenamate NSAID with an antifibrinolytic agent gives clinicians a convenient single-tablet solution, improving patient compliance compared to separate prescriptions. This combination is prescribed across gynecology and primary care, giving it wide prescriber appeal. The 250mg + 250mg strength is the most established formulation in this category. Indian manufacturers producing this combination can serve both domestic and export markets, particularly in Asia, Africa, and Latin America where gynecological health awareness and treatment access are expanding. Manufacturing requires precise quality control to ensure stability of both active ingredients in a single tablet matrix.

This makes Mefenamic Acid + Tranexamic Acid one of the most sought-after gynecological combinations for third party manufacturing in India.